A research team has identified the impact of stem cell infusion timing on the incidence and severity of acute ...

While many recognize Mia Hamm as a legendary soccer player and two-time Olympic gold medalist, she has also become a ...

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a critical therapeutic strategy for treating conditions such as hematological ...

Immunosuppressive therapy improves pancytopenia in severe aplastic anemia.However, its effects are not long-lasting as evidenced by a modest 2-year EFS rate of just 46%, prompting the need for ...

Madeleine R. Heldman, MD, MS, discusses managing cytomegalovirus, including advances in CMV assessment and antiviral and immune strategies.

Mesoblast (MSB:ASX; MESO:Nasdaq) has secured a significant agreement with the U.S. Centers for Medicare & Medicaid Services ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.

While HCT can be curative, it comes with significant risks. One major complication is chronic graft-versus-host disease (cGVHD), which affects up to 30-50% of long-term survivors. This condition ...